Analysis of percentage change in NT-proBNP from baseline in cardiac-evaluable patients (baseline NT-proBNP of ≥650 pg/mL and at least 1 postbaseline NT-proBNP measurement). Cardiac responders are denoted with deep blue bars (>30% and >300 pg/mL decrease in NT-proBNP). No cardiac progressors (>30% and >300 pg/mL increase in NT-proBNP) were identified. Cardiac stable patients are denoted with light blue bars (neither response nor progression). For each individual patient, time since last exposure to antiplasma cell therapy (months), light chain disease type (κ or λ), and hematologic disease status at the time of study enrollment is reported.